Immunovant Inc reports results for the quarter ended in December - Earnings Summary

Immunovant

03/02/2023 12:46

* Immunovant Inc  IMVT.OQ  reported a quarterly adjusted
loss
of 49 cents​​ per share for the quarter ended in December. The
mean expectation of eight analysts for the quarter was for a
loss of 39 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Immunovant Inc's reported EPS for the quarter was a loss
of 49
cents​.
    * The mean earnings estimate of analysts had risen by
about 4.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Immunovant Inc shares had risen by 3.0% this quarter.
    * The company reported a quarterly loss of $62.84 million.
    * Wall Street's median 12-month price target for Immunovant
Inc is
$18.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
3 at 12:46 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.39          -0.49          Missed
 Sep. 30 2022      -0.39          -0.41          Missed
 Jun. 30 2022      -0.40          -0.35          Beat
 Mar. 31 2022      -0.38          -0.41          Missed